Condition: Advanced Solid Malignancy · Sponsor: Grey Wolf Therapeutics
This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.
This description comes directly from the study's public registry record.
Grey Wolf Therapeutics Patient enquiries · +44 1235644970 · enquiries@gwt.bio
Always discuss trial participation with your own doctor first.
| GenesisCare Research | Adelaide, Australia | Withdrawn |
| Southern Oncology Clinical Research Unit (SOCRU) | Bedford Park, Australia | Recruiting |
| Blacktown Hospital | Blacktown, Australia | Recruiting |
| Kinghorn Cancer Centre (KCC) | Darlinghurst, Australia | Recruiting |
| Austin Health | Heidelberg, Australia | Recruiting |
| Alfred Health | Melbourne, Australia | Recruiting |
| Mater Research | South Brisbane, Australia | Recruiting |
| Cancer Care Wollongong | Wollongong, Australia | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Recruiting |
| Institut de Cancérologie de l'Ouest (ICO) | Saint-Herblain, France | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06923761